Overview
- 3 inspections across 3 sites are on record.
- 0 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2021-09-17.
At a glance
Inspections
3
Sites
3
Observations
0
Career since
Oct 2019
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Janssen Pharmaceuticals Inc. | 17 Sep 2021 | Biologics | |
| Juno Therapeutics, Inc. | 16 Oct 2020 | Biologics | On file |
| Emergent BioDefense Operations Lansing LLC | 4 Oct 2019 | Biologics | On file |
Sites inspected
Janssen Pharmaceuticals Inc.Raritan, United States1 insp.
Juno Therapeutics, Inc.Bothell, United States1 insp.
Emergent BioDefense Operations Lansing LLCLansing, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Jacqueline M Diaz Albertini1 shared
Zhaohui Ye1 shared
Lily Y Koo1 shared
Graeme E Price1 shared
Jacqueline M Diaz Albert1 shared
Nirjal Bhattarai1 shared
Kimberly L Schultz1 shared
Rabia Ballica1 shared
Prabhu P Raju1 shared
Eileen A Liu1 shared
Full investigator report
Get the verbatim findings behind David E Bailey's inspection record
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site